

GP# 1614

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1720)

In re Application of:
Asp, et al.

Serial No.: 09/993,211

Filed: November 16, 2001

For: Method for the Treatment of
Cardiotoxicity Induced by Antitumor
Compounds



Examiner: TBA

Art Unit: 1614

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Asst. Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
 - a) Second Supplemental Information Disclosure Statement;
 - b) PTO Form 1449 and 34 cited references;
 - c) Return postcard
2. With respect to fees:
 - a) It is believed no fee is due at this time.
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Asst. Commissioner for Patents, Washington, D.C. 20231 on June 20, 2002.

Date: June 20, 2002

Respectfully submitted,

Lisa M.W. Hillman
Registration No. 43,673



UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1720)

PATENT

In the Application of:

Asp, et al.

Serial No.: 09/993,211

Filed: November 16, 2001

For: Method for the Treatment of
Cardiotoxicity Induced by Antitumor
Compounds

Art Unit: 1614

Examiner: To be assigned

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to the duty of disclosure provided by 35 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of the references are enclosed. Copies are also listed in the PTO-1449 form enclosed herewith. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing from the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any

other representation and, in particular, no representation is indented as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be “prior art” within the meaning of 35 U.S.C. sections 102 or 103.

CITED REFERENCES

Other Documents

- 1) Imondi, et al., *“Dose-Response Relationship of Dexrazoxane for Prevention of Doxorubicin-induced Cardiotoxicity in Mice, Rats and Dogs”*, *Cancer Research*, 56, pp. 4200-4204, 1996
- 2) Tetef, et al., *“Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies”*, *Clinical Cancer Research*, Vol. 7, pp. 1569-1576, 2001
- 3) Keefe, *“Anthracycline-Induced Cardiomyopathy”*, *Seminars in Oncology*, Vol. 28, No. 4, Suppl. 12, pp. 2-7, 2001
- 4) Herman, et al., *“Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats”*, *Cancer Chemother Pharmacol*, 45, pp. 329-334, 2000
- 5) Della Torre, et al., *“Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel”*, *Cancer Chemother Pharmacol*, 44, pp. 138-142, 1999
- 6) Speyer, et al., *“Strategies for Reduction of Anthracycline Cardiac Toxicity”*, *Seminars in Oncology*, Vol. 25, No. 5, pp. 525-537, 1998
- 7) Chvetzoff, et al., *“Prévention de la toxicité”*, *La Presse Médicale*, 27, no. 39, pp. 2106-2112, 1998 (including English abstract)
- 8) Herman, et al., *“Preclinical Animal Models of Cardiac Protection from Anthracycline-Induced Cardiotoxicity”*, *Seminars in Oncology*, Vol. 25, No. 4, Suppl. 10, pp. 15-21, 1998
- 9) Swain, et al., *“Delayed Administration of Dexrazoxane Provides Cardioprotection for Patients with Advanced Breast Cancer Treated with Doxorubicin-Containing Therapy”*, *Journal of Clinical Oncology*, Vol. 15, No. 4, pp. 1333-1340, 1997

- 10) Pouna, et al., "Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention", *British Journal of Pharmacology*, Vol. 117, pp. 1593-1599, 1996
- 11) Venturini, et al., "Multicenter Randomized Controlled Clinical Trial to Evaluate Cardioprotection of Dexrazoxane Versus No Cardioprotection in Women Receiving Epirubicin Chemotherapy for Advanced Breast Cancer", *Journal of Clinical Oncology*, Vol. 14, No. 12, pp. 3112-3120, 1996
- 12) Dorr, "Cytoprotective Agents for Anthracyclines", *Seminars in Oncology*, Vol. 23, No. 4, Suppl. 8, pp. 23-34, 1996
- 13) Shan, et al., "Anthracycline-Induced Cardiotoxicity", *Ann Intern Med.*, 125:47-58, 1996
- 14) Cook-Bruns, "Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer", *Oncology*, 61 (suppl 2):58-66, 2001
- 15) Winer, et al., "New Combinations with Herceptin® in Metastatic Breast Cancer", *Oncology*, 61 (suppl 2):50-57, 2001
- 16) Ewer, et al., "Cardiotoxicity in Patients Receiving Trastuzumab (Herceptin): Primary Toxicity, Synergistic or Sequential Stress, or Surveillance Artifact?", *Seminars in Oncology*, Vol. 26, No. 4, Suppl. 12, pp. 96-101, 1999
- 17) Sparano, "Cardiac Toxicity of Trastuzumab (Herceptin): Implications for the Design of Adjuvant Trials", *Seminars in Oncology*, Vol. 28, No. 1, Suppl. 3, pp. 20-27, 2001
- 18) Chien, "Myocyte Survival Pathways and Cardiomyopathy: Implications for Trastuzumab Cardiotoxicity", *Seminars in Oncology*, Vol. 27, No. 6, Suppl. 11, pp. 9-14, 2000
- 19) Schnitt, "Breast Cancer in the 21st Century: New Opportunities and New Challenges", *Modern Pathology*, Vol. 14, No. 3, pp. 213-218, 2001
- 20) Untch, et al., "Anthrazykline and Herceptin® als neue Therapieoption beim metastasierten Mammakarzinom", *Onkologie*, 23 (suppl 2):15-19, 2000
- 21) Schaller, et al., "Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein", *J. Cancer Res. Clin. Oncol.*, Vol. 125, pp. 520-524, 1999
- 22) Doroshow, et al., "Reactive Oxygen Metabolism Induced by Trastuzumab

(Herceptin®) in Human Breast Cancer Cells", *Molecular Biology*, 29, #4145


- 23) Mladosičová, et al., "Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane", *Neoplasma*, Vol. 48, No. 1, pp. 61-99, 2001
- 24) Anderson, "Which goes first, the electron or the proton?", *Redox Report*, Vol. 5, No. 6, Commentary
- 25) Kwok, et al., "The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity", *Redox Report*, Vol. 5, No. 6, pp. 317-324, 2000
- 26) Lopez, "Dexrazoxane – Attualità e prospettive nella protezione dalla cardiotossicità indotta da chemioterapia", *Clin. Ter.*, 150:37-49, 1999
- 27) Ferrans, et al., "Pathogenesis and Prevention of Doxorubicin Cardiomyopathy", *ЦИТОЛОГИЯ*, Tom 39, No. 10, pp. 928-937, 1997
- 28) Rosing, et al., "Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)", *European Journal of Drug Metabolism and Pharmacokinetics*, Vol. 24, No. 1, pp. 69-77, 1999
- 29) Baldwin, et al., "Dose-Independent Pharmacokinetics of the Cardioprotective Agent Dexrazoxane in Dogs", *Biopharmaceutics & Drug Disposition*, Vol. 17, pp. 541-550, 1996
- 30) Kosty, et al., "High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study – Cancer and Leukemia Group B 9631", *Lung Cancer*, Vol. 34, pp. 289-295, 2001
- 31) Weiss, et al., "Dexrazoxane (ICRF-187)", *Gen. Pharmac.*, Vol. 32, No. 1, pp. 155-158, 1999
- 32) Hasinoff, et al., "Relative Plasma Levels of the Cardioprotective Drug Dexrazoxane and its Two Active Ring-Opened Metabolites in the Rat", *Drug Metabolism and Disposition*, Vol. 27, No. 2, 1999

- 33) Seymour, et al., "*Use of dexrazoxane as a Cardioprotectant in Patients Receiving Doxorubicin or Epirubicin Chemotherapy for the Treatment of Cancer*", The Provincial Systemic Treatment Disease Site Group, *Cancer Prev. Control*, 3(2):145-59, 1999 – Abstract Only
- 34) Květina, et al., "*Preclinical comparison of bis-diketopiperazine-propane (dexrazoxane) and bis-diketopiperazine-ethane (antimet) on the adriamycin-cardiotoxic effect*", *Neoplasma*, Vol. 44, No. 2, pp. 97-99, 1997

Respectfully submitted,

Date: June 20, 2002

by:


Lisa M.W. Hillman
Reg. No. 43,673

FORM PTO-1449
(R v. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. D cket N .

Serial No.

01-1720

09/993,211

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

Applicant:

Asp, et al.

Filing Date:

November 16, 2001

Group:

1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appr priat

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translati n
					Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

1. \	Imondi, et al., "Dose-Response Relationship of Dexrazoxane for Prevention of Doxorubicin-induced Cardiotoxicity in Mice, Rats and Dogs", <i>Cancer Research</i> , 56, pp. 4200-4204, 1996
2. \	Tetef, et al., "Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies", <i>Clinical Cancer Research</i> , Vol. 7, pp. 1569-1576, 2001
3. \	Keefe, "Anthracycline-Induced Cardiomyopathy", <i>Seminars in Oncology</i> , Vol. 28, No. 4, Suppl. 12, pp. 2-7, 2001
4. \	Herman, et al., "Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats", <i>Cancer Chemother Pharmacol</i> , 45, pp. 329-334, 2000
5. \	Della Torre, et al., "Cardioprotection by dexrazoxane in rats treated wiuth doxorubicin and paclitaxel", <i>Cancer Chemother Pharmacol</i> , 44, pp. 138-142, 1999
6. \	Speyer, et al., "Strategies for Reduction of Anthracycline Cardiac Toxicity", <i>Seminars in Oncology</i> , Vol. 25, No. 5, pp. 525-537, 1998
7. \	Chvetzoff, et al., "Prévention de la toxicité", <i>La Presse Médicale</i> , 27, no. 39, pp. 2106-2112, 1998 (including English abstract)
8. \	Herman, et al., "Preclinical Animal Models of Cardiac Protection from Anthracycline-Induced Cardiotoxicity", <i>Seminars in Oncology</i> , Vol. 25, No. 4, Suppl. 10, pp. 15-21, 1998
9. \	Swain, et al., "Delayed Administration of Dexrazoxane Provides Cardioprotection for Patients with Advanced Breast Cancer Treated with Doxorubicin-Containing Therapy", <i>Journal of Clinical Oncology</i> , Vol. 15, No. 4, pp. 1333-1340, 1997




	Pouna, et al., "Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention", <i>British Journal of Pharmacology</i> , Vol. 117, pp. 1593-1599, 1996
	Venturini, et al., "Multicenter Randomized Controlled Clinical Trial to Evaluate Cardioprotection of Dexrazoxane Versus No Cardioprotection in Women Receiving Epirubicin Chemotherapy for Advanced Breast Cancer", <i>Journal of Clinical Oncology</i> , Vol. 14, No. 12, pp. 3112-3120, 1996
12.	Dorr, "Cytoprotective Agents for Anthracyclines", <i>Seminars in Oncology</i> , Vol. 23, No. 4, Suppl. 8, pp. 23-34, 1996
13.	Shan, et al., "Anthracycline-Induced Cardiotoxicity", <i>Ann Intern Med.</i> , 125:47-58, 1996
14.	Cook-Bruns, "Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer", <i>Oncology</i> , 61 (suppl 2):58-66, 2001
15.	Winer, et al., "New Combinations with Herceptin® in Metastatic Breast Cancer", <i>Oncology</i> , 61 (suppl 2):50-57, 2001
16.	Ewer, et al., "Cardiotoxicity in Patients Receiving Trastuzumab (Herceptin): Primary Toxicity, Synergistic or Sequential Stress, or Surveillance Artifact?", <i>Seminars in Oncology</i> , Vol. 26, No. 4, Suppl. 12, pp. 96-101, 1999
17.	Sparano, "Cardiac Toxicity of Trastuzumab (Herceptin): Implications for the Design of Adjuvant Trials", <i>Seminars in Oncology</i> , Vol. 28, No. 1, Suppl. 3, pp. 20-27, 2001
18.	Chien, "Myocyte Survival Pathways and Cardiomyopathy: Implications for Trastuzumab Cardiotoxicity", <i>Seminars in Oncology</i> , Vol. 27, No. 6, Suppl. 11, pp. 9-14, 2000
19.	Schnitt, "Breast Cancer in the 21 st Century: New Opportunities and New Challenges", <i>Modern Pathology</i> , Vol. 14, No. 3, pp. 213-218, 2001
20.	Untch, et al., "Anthracycline and Herceptin® als neue Therapieoption beim metastasierten Mammakarzinom", <i>Onkologie</i> , 23 (suppl 2):15-19, 2000
21.	Schaller, et al., "Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein", <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 125, pp. 520-524, 1999
22.	Doroshov, et al., "Reactive Oxygen Metabolism Induced by Trastuzumab (Herceptin®) in Human Breast Cancer Cells", <i>Molecular Biology</i> , 29, #4145
23.	Mladosiévičová, et al., "Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane", <i>Neoplasma</i> , Vol. 48, No. 1, pp. 61-99, 2001
24.	Anderson, "Which goes first, the electron or the proton?", <i>Redox Report</i> , Vol. 5, No. 6, Commentary
25.	Kwok, et al., "The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity", <i>Redox Report</i> , Vol. 5, No. 6, pp. 317-324, 2000
26.	Lopez, "Dexrazoxane - Attualità e prospettive nella protezione dalla cardiotossicità indotta da chemioterapia", <i>Clin. Ter.</i> , 150:37-49, 1999
27.	Ferrans, et al., "Pathogenesis and Prevention of Doxorubicin Cardiomyopathy", <i>Cardiology</i> , Tom 39, No. 10, pp. 928-937, 1997
28.	Rosing, et al., "Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)", <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , Vol. 24, No. 1, pp. 69-77, 1999
29.	Baldwin, et al., "Dose-Independent Pharmacokinetics of the Cardioprotective Agent Dexrazoxane in Dogs", <i>Biopharmaceutics & Drug Disposition</i> , Vol. 17, pp. 541-550, 1996
30.	Kosty, et al., "High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study - Cancer and Leukemia Group B 9631", <i>Lung Cancer</i> , Vol. 34, pp. 289-295, 2001
31.	Weiss, et al., "Dexrazoxane (ICRF-187)", <i>Gen. Pharmac.</i> , Vol. 32, No. 1, pp. 155-158, 1999
32.	Hasinoff, et al., "Relative Plasma Levels of the Cardioprotective Drug Dexrazoxane and its Two Active Ring-Opened Metabolites in the Rat", <i>Drug Metabolism and Disposition</i> , Vol. 27, No. 2, 1999
33.	Seymour, et al., "Use of dexrazoxane as a Cardioprotectant in Patients Receiving Doxorubicin or Epirubicin Chemotherapy for the Treatment of Cancer", The Provincial Systemic Treatment Disease Site Group, <i>Cancer Prev. Control</i> , 3(2):145-59, 1999 - Abstract Only
34.	Kvitina, et al., "Preclinical comparison of bis-diketopiperazine-propane (dexrazoxane) and bis-diketopiperazine-ethane (antimet) on the adriamycin-cardiotoxic effect", <i>Neoplasma</i> , Vol. 44, No. 2, pp. 97-99, 1997

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900



EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900